10-Q: Lifeward (ReWalk Robotics) Reports Strong Q1 Revenue Growth Following AlterG Acquisition and Medicare Policy Change

Lifeward, formerly ReWalk Robotics, saw a 340% increase in revenue in Q1 2024 compared to Q1 2023, driven by the acquisition of AlterG and positive changes in Medicare reimbursement policies.

Summary

• Lifeward, previously known as ReWalk Robotics, reported a significant revenue increase of 340% in the first quarter of 2024, reaching $5.3 million, compared to $1.23 million in the same period last year.
• This growth was primarily fueled by the acquisition of AlterG, which contributed $2.8 million in revenue, and increased sales of ReWalk Personal exoskeletons due to expanded Medicare coverage.
• The company's gross profit margin was 26.4%, which included $0.4 million in amortization of intangible assets, and excluding this, the gross profit margin was 33.7%, a decrease from 46.4% in Q1 2023 due to lower AlterG sales volume and an adverse mix of ReWalk system sales.
• Operating expenses increased to $7.9 million, up from $4.9 million in the prior year, due to higher research and development costs, increased sales and marketing expenses, and amortization of intangible assets.
• The company reported a net loss of $6.3 million, or $0.73 per share, compared to a net loss of $4.3 million, or $0.51 per share, in the first quarter of 2023.
• Lifeward had $20.7 million in cash and cash equivalents as of March 31, 2024, and a negative operating cash flow of $7.7 million for the quarter.
• The company expects to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants, or a combination of these methods.
• A one-for-seven reverse share split was implemented on March 15, 2024, which is reflected in all share and per share data.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and positive developments in Medicare reimbursement, but the company is still operating at a loss and has significant expenses. The sentiment is positive overall, but with some caution due to the financial challenges.

Positives

• The company experienced a substantial increase in revenue, primarily due to the AlterG acquisition and expanded Medicare coverage for ReWalk Personal exoskeletons.
• The finalization of the Medicare Home Health Rule and the establishment of a lump-sum payment rate for personal exoskeletons are expected to positively impact future sales.
• The company has sufficient funds to support operations for more than 12 months following the issuance date of the financial statements.
• The company is actively pursuing various paths for coverage and reimbursement from third-party payors.

Negatives

• The company reported a net loss of $6.3 million for the quarter.
• Gross profit margin decreased to 26.4% (or 33.7% excluding amortization), primarily due to lower AlterG sales volume and an adverse mix of ReWalk system sales.
• Operating expenses increased significantly, driven by higher R&D, sales, and marketing costs.
• The company has a negative operating cash flow of $7.7 million for the quarter.

Risks

• The company's transition to profitability is dependent on the successful development and commercialization of its products, the establishment of distribution contracts, and potential acquisitions.
• The company may need to raise additional capital through private or public offerings, warrant exercises, or strategic partnerships.
• There is no guarantee that the company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
• The company is subject to limitations under Form S-3 rules, which may constrain its ability to secure capital through public offerings.
• The company's future cash requirements will depend on various factors, including revenue growth, sales and marketing activities, R&D spending, and potential acquisitions.
• The company is exposed to risks related to the ongoing war between Israel and Hamas and increasing tensions between China and Taiwan.

Future Outlook

The company expects future growth to be driven by sales of the ReWalk Personal device through expanded coverage and reimbursement, as well as sales of AlterG anti-gravity systems and distributed products. The company also intends to focus on new product development and expanding its market reach.

Management Comments

• The company is focused on expanding reimbursement coverage for its ReWalk Personal Exoskeleton device.
• The company is working to integrate and unify the sales and marketing resources of the ReWalk and AlterG organizations.
• The company is advancing the FDA submission for clearance of the ReWalk 7 next-generation exoskeleton model.
• The company is developing a new entry-level model of the AlterG system designed for smaller independent clinics.

Industry Context

The announcement reflects a positive shift in the medical device industry, particularly in the area of rehabilitation technology, with increased acceptance and reimbursement for exoskeleton devices. The acquisition of AlterG positions Lifeward as a more diversified player in the rehabilitation market, and the Medicare policy change is a significant step forward for the industry.

Comparison to Industry Standards

• The 340% revenue growth is significantly higher than the average growth rate for medical device companies, indicating a strong performance in the quarter.
• The gross profit margin of 26.4% (or 33.7% excluding amortization) is lower than some established medical device companies, but this is likely due to the integration of AlterG and the early stages of the Medicare reimbursement process.
• The company's operating expenses are higher than some competitors, reflecting the investment in R&D and sales and marketing activities.
• The net loss is not uncommon for companies in the growth phase, particularly those investing heavily in new product development and market expansion.
• The company's cash position of $20.7 million is adequate for the near term, but it will likely need to raise additional capital to support its growth plans.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and potential for future growth, but they should be aware of the company's ongoing losses and need for additional capital.
• Employees will benefit from the company's growth and expansion, but they may also face challenges related to the integration of AlterG.
• Customers will benefit from the expanded availability of the company's products and the potential for increased reimbursement coverage.
• Suppliers may benefit from the company's increased sales and production volume.
• Creditors should be aware of the company's ongoing losses and need for additional capital.

Next Steps

• The company will focus on expanding reimbursement coverage for its ReWalk Personal Exoskeleton device.
• The company will continue to integrate and unify the sales and marketing resources of the ReWalk and AlterG organizations.
• The company will advance the FDA submission for clearance of the ReWalk 7 next-generation exoskeleton model.
• The company will continue product development activity for its AlterG Anti-Gravity systems, including a new entry-level model.

Key Dates

Keywords

exoskeleton, rehabilitation, medical devices, Medicare, AlterG, revenue growth, spinal cord injury, stroke, reimbursement, reverse stock split